東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Management of chemotherapy-induced n...

Navari, Rudolph M.

Linked to FindBook

Google Book

Amazon

博客來

Management of chemotherapy-induced nausea and vomiting = new agents and new uses of current agents /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Management of chemotherapy-induced nausea and vomiting/ edited by Rudolph M. Navari.
Reminder of title:	new agents and new uses of current agents /
other author:	Navari, Rudolph M.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	viii, 181 p. :ill., digital ;24 cm.
[NT 15003449]:	1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
Contained By:	Springer eBooks
Subject:	Cancer - Chemotherapy -
Online resource:	http://dx.doi.org/10.1007/978-3-319-27016-6
ISBN:	9783319270166$q(electronic bk.)

Management of chemotherapy-induced nausea and vomiting = new agents and new uses of current agents /
Management of chemotherapy-induced nausea and vomitingnew agents and new uses of current agents /[electronic resource] :edited by Rudolph M. Navari. - Cham :Springer International Publishing :2016. - viii, 181 p. :ill., digital ;24 cm.

1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.

This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.

ISBN: 9783319270166$q(electronic bk.)

Standard No.: 10.1007/978-3-319-27016-6doiSubjects--Topical Terms:

2018792
Cancer
--Chemotherapy

LC Class. No.: RC271.C5

Dewey Class. No.: 616.994061

Management of chemotherapy-induced nausea and vomiting = new agents and new uses of current agents /
LDR:03412nmm a2200313 a 4500 001 2030592
003 DE-He213
005 20160817140904.0
006 m d
007 cr nn 008maaau
008 160908s2016 gw s 0 eng d
020 $a 9783319270166$q(electronic bk.)
020 $a 9783319270142$q(paper)
024 7 $a 10.1007/978-3-319-27016-6 $2 doi
035 $a 978-3-319-27016-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b M266 2016
245 0 0 $a Management of chemotherapy-induced nausea and vomiting $h [electronic resource] : $b new agents and new uses of current agents / $c edited by Rudolph M. Navari.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2016.
300 $a viii, 181 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
520 $a This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
650 0 $a Cancer $x Chemotherapy $x Complications. $3 2018792
650 0 $a Nausea $x Chemotherapy. $3 2182512
650 0 $a Vomiting $x Chemotherapy. $3 2182513
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Oncology. $3 751006
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Pharmacotherapy. $3 1978501
700 1 $a Navari, Rudolph M. $3 2182511
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-27016-6
950 $a Medicine (Springer-11650)